FDA Approves Expanded Pediatric Indication for HIV Treatment Regimen

By NewsDesk @bactiman63 Gilead Sciences, Inc. today announced the U.S. Food and Drug Administration (FDA) approved a new low-dose tablet dosage form of Biktarvy(R) (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing at least 14 kg to less than 25 kg who are virologically suppressed or new to antiretroviral therapy. The approval [...]

The post FDA Approves Expanded Pediatric Indication for HIV Treatment Regimen appeared first on Outbreak News Today.